UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

Arthritis research & therapy, 2021-02, Vol.23 (1), p.51-51, Article 51

2021

Volltextzugriff (PDF)

A novel thin film polarizer from photocurable non-aqueous lyotropic chromonic liquid crystal solutions

Journal of materials chemistry, 2011-01, Vol.21 (7), p.2074-2077

2011

Volltextzugriff (PDF)

Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects

Clinical and translational science, 2021-07, Vol.14 (4), p.1280-1291

2021

Volltextzugriff (PDF)

Synthesis of New Chiral Chromonic Lyotropic Liquid Crystal Based on Perylenebis(dicarboximide)

Bulletin of the Korean Chemical Society, 2009, 30(4), , pp.935-937

2009

Volltextzugriff (PDF)

Effect of Wash Treatments on Reducing Human Norovirus on Iceberg Lettuce and Perilla Leaf

Journal of food protection, 2011-11, Vol.74 (11), p.1908-1911

2011

Volltextzugriff (PDF)

Characterization of a Putative Thioredoxin Peroxidase Prx1 of Candida albicans

Molecules and Cells, 2012, 33(3), , pp.301-307

2012

Volltextzugriff (PDF)

Construction of Saccharomyces cerevisiae strains with enhanced ethanol tolerance by mutagenesis of the TATA-binding protein gene and identification of novel genes associated with ethanol tolerance

Biotechnology and bioengineering, 2011-08, Vol.108 (8), p.1776-1787

2011

Volltextzugriff (PDF)

Color Tuning of Perylene Based Lyotropic Chromonic Liquid Crystal

Bulletin of the Korean Chemical Society, 2009, 30(1), , pp.224-226

2009

Volltextzugriff (PDF)

Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects

British journal of clinical pharmacology, 2021-11, Vol.87 (11), p.4323-4333

2021

Volltextzugriff (PDF)

Effects of Gene Orientation and Use of Multiple Promoters on the Expression of XYL1 and XYL2 in Saccharomyces cerevisiae

Applied biochemistry and biotechnology, 2008-03, Vol.145 (1-3), p.69-78

2008

Volltextzugriff (PDF)

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD STUDY

Gastroenterology (New York, N.Y. 1943), 2024-02, Vol.166 (3), p.S13

2024

Volltextzugriff (PDF)

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD AND LIBERTY-UC STUDY

Gastroenterology (New York, N.Y. 1943), 2024-02, Vol.166 (3), p.S11-S12

2024

Volltextzugriff (PDF)

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study

Expert opinion on investigational drugs, 2023-05, Vol.32 (5), p.429-439

2023

Volltextzugriff (PDF)

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

Rheumatology (Oxford, England), 2019-12, Vol.58 (12), p.2193-2202

2019

Volltextzugriff (PDF)

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

Rheumatology (Oxford, England), 2022-04, Vol.61 (4), p.1385-1395

2022

Volltextzugriff (PDF)

A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males

Expert opinion on biological therapy, 2024-07, Vol.24 (7), p.655-663

2024

Volltextzugriff (PDF)

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD AND LIBERTY-UC STUDY

Inflammatory bowel diseases, 2024-01, Vol.30 (Supplement_1), p.S8-S9

2024

Volltextzugriff (PDF)

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD STUDY

Inflammatory bowel diseases, 2024-01, Vol.30 (Supplement_1), p.S00-S00

2024

Volltextzugriff (PDF)

Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults

Immunotherapy, 2023-02, Vol.15 (3), p.149-161

2023

Volltextzugriff (PDF)

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

The Lancet. Haematology, 2017-08, Vol.4 (8), p.e362-e373

2017

Volltextzugriff (PDF)

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019

Open forum infectious diseases, 2022-08, Vol.9 (8), p.ofac406-ofac406

2022

Volltextzugriff (PDF)

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

Blood, 2016-12, Vol.128 (22), p.1807-1807

2016

Volltextzugriff (PDF)

546. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S375-S375

2021

Volltextzugriff (PDF)

Optimization of recombinant human platelet-derived growth factor-BB encapsulated in Poly (lactic-co-glycolic acid) microspheres for applications in wound healing

조직공학과 재생의학, 2016, 13(1), 13, pp.13-20

2016

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(86)

Publikationsform

Sprache

Englisch
(112)
Koreanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

A novel thin film polarizer from photocurable non-aqueous lyotropic chromonic liquid crystal solutions

Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects

Synthesis of New Chiral Chromonic Lyotropic Liquid Crystal Based on Perylenebis(dicarboximide)

Effect of Wash Treatments on Reducing Human Norovirus on Iceberg Lettuce and Perilla Leaf

Characterization of a Putative Thioredoxin Peroxidase Prx1 of Candida albicans

Construction of Saccharomyces cerevisiae strains with enhanced ethanol tolerance by mutagenesis of the TATA-binding protein gene and identification of novel genes associated with ethanol tolerance

Color Tuning of Perylene Based Lyotropic Chromonic Liquid Crystal

Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects

Effects of Gene Orientation and Use of Multiple Promoters on the Expression of XYL1 and XYL2 in Saccharomyces cerevisiae

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD STUDY

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD AND LIBERTY-UC STUDY

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD AND LIBERTY-UC STUDY

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD STUDY

Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

546. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial

Optimization of recombinant human platelet-derived growth factor-BB encapsulated in Poly (lactic-co-glycolic acid) microspheres for applications in wound healing

Suchergebnisse filtern